ID: ALA492977

Max Phase: Preclinical

Molecular Formula: C21H20O4

Molecular Weight: 336.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cccc(/C=C/C(=O)/C=C(O)/C=C/c2cccc(OC)c2)c1

Standard InChI:  InChI=1S/C21H20O4/c1-24-20-7-3-5-16(13-20)9-11-18(22)15-19(23)12-10-17-6-4-8-21(14-17)25-2/h3-15,22H,1-2H3/b11-9+,12-10+,18-15-

Standard InChI Key:  PESKYAXDUKYINS-ZFULPTHRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 336.39

Molecular Weight (Monoisotopic): 336.1362

AlogP: 4.44

#Rotatable Bonds: 7

Polar Surface Area: 55.76

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.32

CX Basic pKa:

CX LogP: 4.37

CX LogD: 4.36

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.46

Np Likeness Score: 0.55

References

1. Fuchs JR, Pandit B, Bhasin D, Etter JP, Regan N, Abdelhamid D, Li C, Lin J, Li PK..  (2009)  Structure-activity relationship studies of curcumin analogues.,  19  (7): [PMID:19249204] [10.1016/j.bmcl.2009.01.104]

2. Leow PC, Bahety P, Boon CP, Lee CY, Tan KL, Yang T, Ee PL..  (2014)  Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway.,  71  [PMID:24275249] [10.1016/j.ejmech.2013.10.073]

3. Ye N, Ding Y, Wild C, Shen Q, Zhou J..  (2014)  Small molecule inhibitors targeting activator protein 1 (AP-1).,  57  (16): [PMID:24831826] [10.1021/jm5004733]

4. Orteca G, Tavanti F, Bednarikova Z, Gazova Z, Rigillo G, Imbriano C, Basile V, Asti M, Rigamonti L, Saladini M, Ferrari E, Menziani MC..  (2018)  Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases.,  26  (14): [PMID:30031653] [10.1016/j.bmc.2018.07.027]

Source

Source(1):

• Scientific Literature